Idiopathic Pulmonary Fibrosis: Best Practice in Monitoring and Managing a Relentless Fibrotic Disease release_tjl5j4haabftvpn26d4t2yw3qm

by Wim A. Wuyts, Marlies Wijsenbeek, Benjamin Bondue, Demosthenes Bouros, Paul Bresser, Carlos  Robalo Cordeiro, Ole Hilberg, Jesper Magnusson, Effrosyni D. Manali, António Morais, Spyridon Papiris, Saher Shaker (+2 others)

Published in Respiration by S. Karger AG.

2019   Volume 99, Issue 1, p1-10


Idiopathic pulmonary fibrosis (IPF) is a fibrosing interstitial lung disease that is, by definition, progressive. Progression of IPF is reflected by a decline in lung function, worsening of dyspnea and exercise capacity, and deterioration in health-related quality of life. In the short term, the course of disease for an individual patient is impossible to predict. A period of relative stability in forced vital capacity (FVC) does not mean that FVC will remain stable in the near future. Frequent monitoring using multiple assessments, not limited to pulmonary function tests, is important to evaluate disease progression in individual patients and ensure that patients are offered appropriate care. Optimal management of IPF requires a multidimensional approach, including both pharmacological therapy to slow decline in lung function and supportive care to preserve patients' quality of life.
In text/plain format

Archived Files and Locations

application/pdf  597.6 kB
file_zaueibymhzhxbix6hlo4xgaswa (web) (webarchive)
application/pdf  597.6 kB
file_u5yzezufabewjlym5xdnmzsfie (web) (webarchive)
application/pdf  597.3 kB
file_3vxiozwnojc7xdytjzkz5zwffe (web) (webarchive)
Read Archived PDF
Type  article-journal
Stage   published
Date   2019-12-12
Language   en ?
DOI  10.1159/000504763
PubMed  31830755
PMC  PMC6979429
Container Metadata
Not in DOAJ
In Keepers Registery
ISSN-L:  0025-7931
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: 6d029e33-4b84-47e6-90cd-fc4770eed7ef